Impact of transcatheter aortic valve implantation on coexistent mitral regurgitation parameters

Data on the impact of transcatheter aortic valve implantation (TAVI) on coexisting mitral regurgitation (MR) are still inconsistent.

The study aimed to evaluate the impact of TAVI on coexistent MR depending on its etiology.

Out of 311 patients treated with TAVI, we selected 48 with coexistent MR: functional (FMR; n = 26) or nonfunctional (nFMR; n = 22). The impact of the procedure on MR was quantitatively assessed during a 1‑year follow‑up using MR effective regurgitant orifice area (MR‑EROA) and volume (MRV).

Compared with baseline, no change of MR‑EROA was observed at 1‑year follow‑up in all patients with MR (median [interquartile range (IQR)], 0.2 [0.17-0.23]cm2 vs 0.17 [0.14-0.2]cm2 ; P = 0.054). No change in MR‑EROA was also noted either in FMR (median [IQR], 0.21 [0.17-0.27]cm2 vs 0.19 [0.14-0.25]cm2 ; P = 0.142) or nFMR (median [IQR], 0.17 [0.12-0.23] cm2 vs 0.17 [0.1-0.2] cm2 ; P = 0.238) cohorts. Decreased MRV was seen in theoverall MR population after TAVI (median [IQR], 32 [28-36]ml/beat vs 26 [22-28]ml/beat; P = 0.002). Similarly, decreased MRV was noted in both FMR (median [IQR], 33 [26-42] ml/beat vs 26 [20-40] ml/beat; P = 0.042) and nFMR (median [IQR], 30 [20-46] ml/beat vs 24 [15-33] ml/beat; P = 0.015) cohorts.

Transcatheter aortic valve implantation had no impact on MR‑EROA regardless of the etiology of regurgitation. However, the procedure reduced MRV in both FMR and nFMR.